BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE | A212756 | DIFGEN PHARMACEUTICALS LLC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Indivior Inc. et al v. Aveva Drug Delivery Systems, Inc. et al 4 patentsANDA 212756buprenorphine hydrochloride and naloxone hydrochloride | S.D. Fla. | 2019-03-22 | Terminated 2019-11-19 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$4.20
per ea
Lowest NADAC/Unit
$1.28
per ea
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 50742036530BUPRENORPHINE-NALOXONE 12-3 MG SL FILM | $4.20 | EA | Generic | — | 2026-06-17 |
| 50742039830BUPRENORPHINE-NALOXONE 4-1 MG SL FILM | $2.27 | EA | Generic | — | 2026-06-17 |
| 50742036430BUPRENORPHINE-NALOXONE 8-2 MG SL FILM | $2.06 | EA | Generic | — | 2026-06-17 |
| 50742039730BUPRENORPHINE-NALOXONE 2-0.5 MG SL FILM | $1.28 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.